Novel drug interactions at D2 dopamine receptors: Modulation of [3H]quinpirole binding by monoamine oxidase inhibitors

Life Sciences

Volumn 71, Issue 23, 2002, Pages 2691-2700

  Levant, Beth ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

D2 dopamine receptor; Monoamine oxidase inhibitor; Quinpirole

Indexed keywords

2 AMINO 6,7 DIHYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFEBUTAMONE; AMITRIPTYLINE; BROMOCRIPTINE; BUTACLAMOL; CLORGYLINE; DEBRISOQUINE; DOPAMINE 2 RECEPTOR; DOXEPIN; FLUOXETINE; HALOPERIDOL; IPRONIAZID; ISOCARBOXAZID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N (2 AMINOETHYL) 4 CHLOROBENZAMIDE; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; NIALAMIDE; PARGYLINE; PHENELZINE; PHENYLBIGUANIDE; PROCAINAMIDE; PSYCHOSTIMULANT AGENT; QUINPIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

BINDING SITE; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; MENTAL DISEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; REGULATORY MECHANISM; SCHIZOPHRENIA; SHORT SURVEY;

EID: 0037175058     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02109-4     Document Type: Review

References (56)

1. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacological Reviews. 49:1997;231-252.
2. Baldessarini R.J., Tarazi F.I. Drugs and the treatment of psychiatric disorders: psychosis and mania. Hardman J.G., Limbird L.E., Gilman A.G. The Pharmacological Basis of Therapeutics. 2001;485-520 McGraw-Hill, New York.
3. Standeart D.G., Young A.B. Treatment of central nervous system degenerative disorders. Hardman J.G., Limbird L.E., Gilman A.G. The Pharmacological Basis of Therapeutics. 2001;549-568 McGraw-Hill, New York.
4. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine receptors and brain function. Neuropharmacology. 35:1996;1503-1519.
5. 2 dopamine receptors from the high-to low-affinity state for dopamine agonists using sodium ions and guanine nucleotides. Journal of Neurochemistry. 44:1985;1925-1935.
6. Levant B. Distribution of dopamine receptor subtypes in the CNS. Stone T.W. CNS Neurotransmitters and Neuromodulators. Dopamine. 1996;77-87 CRC Press, Boca Raton.
7. Bach N.J., Lornfeld E.C., Jones N.D., Chaney M.O., Dorman D.E., Paschal J.W., Clemens J.A., Smalstig E.B. Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-animoethyl)pyrazoles as dopamine agonists. Journal of Medicinal Chemistry. 23:1980;481-491.
8. Titus R.D., Kornfeld E.C., Jones N.D., Clemens J.A., Smaltstig E.B., Fuller R.W., Hahn R.A., Hynes M.D., Mason N.R., Wong D.T., Foreman M.M. Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinloine. Journal of Medicinal Chemistry. 26:1983;1112-1116.
9. Arnt J., Hyttel J., Perregaard J. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. European Journal of Pharmacology. 133:1987;137-145.
10. Dall S., Gandolfi O., Vaccheri A., Roncada P., Montanaro N. Changes in behavioral responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats. Psychopharmacology. 95:1988;81-385.
11. Eilam D., Golani I., Szechtman H. D2-agonist quinpirole induces perseveration of routes and hyperactivity but no perseveration of movements. Brain Research. 490:1989;255-267.
12. Eilam D., Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. European Journal of Pharmacology. 161:1989;151-157.
13. White N.M., Packard M.G., Seamans J. Memory enhancement by post-training peripheral administration of low doses of dopamine agonists: possible autoreceptor effect. Behavioral Neural Biology. 59:1993;230-241.
14. Bushnell P.J., Levin E.D. Effects of dopaminergic drugs on working and reference memory in rats. Pharmacology Biochemistry and Behavior. 45:1993;765-776.
15. Kostrzewa R.M., Brus R., Kalbfleisch J. Ontogenetic homologous sensitization to the antinociceptive action of quinpirole in rats. European Journal of Pharmacology. 209:1991;157-161.
16. Cagiano R., Barfield R.J., White N.R., Pleim E.T., Cuomo V. Mediation of rat postejaculatory 22 kHz ultrasonic vocalization by dopamine D2 receptors. Pharmacology Biochemistry and Behavior. 34:1989;53-58.
17. Segal D.S., Schuckit M.S. Animal models of stimulant-induced psychosis. Creese I. Stimulants: Neurochemical, Behavioral, and Clinical Perspectives. 1983;131-167 Raven Press, New York.
18. Szechtman H., Talangbayan H., Canaran G., Dai H., Eilam D. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmacology. 115:1994;95-104.
19. Szumlinski K.K., Allan M., Talangbayan H., Tracey A., Szechtman H. Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology. 134:1997;193-200.
20. Willner P., Papp S., Cheeta S., Muscat R. Environmental influences on behavioral sensitization in to the dopamine agonist quinpirole. Behavioral Pharmacology. 3:1992;43-50.
21. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research Reviews. 11:1986;157-198.
22. 3 receptors in rat brain. European Journal of Pharmacology. 211:1992;189-194.
23. 2-like dopamine receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics. 262:1992;929-935.
24. 3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. Journal of Pharmacology and Experimental Therapeutics. 264:1993;991-1001.
25. 3H]quinpirole. European Journal of Pharmacology. 203:1991;105-109.
26. Itzhak Y., Stein I., Zhang S.-H., Kassim C.O., Cristante D. Binding of σ-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of σ-receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 257:1991;141-148.
27. 3 receptors: effects of ions and guanine nucleotides. Journal of Pharmacology and Experimental Therapeutics. 274:1995;790-797.
28. 3H]quinpirole binding in rat striatal membranes. European Journal of Pharmacology. 246:1993;171-178.
29. 3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. Journal of Pharmacology and Experimental Therapeutics. 278:1996;145-153.
30. Da Prada M., Kettler R., Keller H.H., Burkhard W.P., Muggli-Maniglio D., Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics. 248:1989;400-414.
31. A-deficient mice. Life Sciences. 70:2001;229-241.
32. 3H]quinpirole binding by a monoamine oxidase inhibitor in subcellular fractions of rat striatum. Life Sciences. 63:1998;1643-1651.
33. Fang J., Yu P. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology. 33:1994;763-768.
34. 3H]-idazoxan binding sites in the rat brain. British Journal of Pharmacology. 108:1993;597-603.
35. Strange P.G. Dopamine receptors: structure and function. Progress in Brain Research. 99:1993;167-179.
36. 2 receptors. Journal of Neurochemistry. 59:1992;627-635.
37. Dahl S.G., Edvardsen O., Sylte I. Molecular dynamics of dopamine at the D2 receptor. Proceedings of the National Academy of Science. 88:1991;8111-8115.
38. 2 dopamine receptor is exposed in the binding-site crevice. Proceedings of the National Academy of Science. 91:1994;10355-10359.
39. 2 receptor. European Journal of Pharmacology. 227:1992;205-214.
40. 2 receptor affinity for drugs and inhibition of adenylyl cyclase. Molecular Pharmacology. 39:1991;733-739.
41. 35S]GTPγS binding: discrepancy with receptor binding profile. European Journal of Pharmacology. 392:2000;125-128.
42. Culver K.E., Szechtman H. Monoamine oxidase inhibitor sensitive site implicated in sensitization to quinpirole. European Journal of Pharmacology. 339:1997;109-111.
43. Culver K.E., Szechtman H. Chronic Ro 41-1049 treatment blocks quinpirole-induced locomotor sensitization. Society for Neuroscience Abstracts. 26:2000;2249.
44. Culver K.E., Rosenfled J.M., Szechtman H. A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats. Psychopharmacology. 151:2000;202-210.
45. Szechtman H., Sulis W., Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behavioral Neuroscience. 112:1998;1475-1485.
46. Szechtman H., Eckert M.J., Tse W.S., Boersma J.T., Bonura C.A., McClelland J.Z., Culver K.E., Eilam D. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neuroscience. 2:2001;4.
47. Liebowitz M.R., Hollander E., Schneier F., Campeas R., Welkowitz L., Hatterer J., Fallon B. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatry. Scandinavia. (Suppl. 360):1990;24-29.
48. Jenike M.A. MAOI for obsessive compulsive disorder [letter]. British Journal of Psychiatry. 140:1982;549.
49. Jaine V.K., Swinson R.P., Thomas J.G. Phenelzine in obsessional neurosis. British Journal of Psychiatry. 117:1970;237-238.
50. Jenike M.A., Baer L., Minichiello W.E., Rauch S.L., Buttolph M.L. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. American Journal of Psychiatry. 154:1997;1261-1264.
51. Robinson T.E. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews. 18:1993;247-291.
52. Angrist B. Psychosis induced by central nervous system stimulants and related drugs. Creese I. Stimulants: neurochemical, behavioral and clinical perspectives. 1983;1-30 Raven Press, New York.
53. Antelman S.M. Stressor-induced sensitization to subsequent stress: implications for the development and treatment of clinical disorders. Kalivas P.W., Barnes C.D. Sensitization in the Nervous System. 1988;227-254 Telford Press, Caldwell, NJ.
54. Kokkinidis L., Anisman H. Amphetamine models of amphetamine paranoid schizophrenia: an overview and elaboration of animal experimentation. Psychological Bulletin. 88:1980;551-579.
55. Post R.M., Contel N.R. Cocaine-induced behavioral sensitization: a model for recurrent manic illness. Perris C., Struwe G., Jansson B. Biological Psychiatry. 1981;746-749 Elsevier, Amsterdam.
56. Thase M.E., Trivedi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 12:1995;185-219.